symtuza
Selected indexed studies
- Symtuza(®) in clinical practice. (Enferm Infecc Microbiol Clin (Engl Ed), 2018) [PMID:30545470]
- Pharmacology of Symtuza(®) (DRV/c/FTC/TAF). (Enferm Infecc Microbiol Clin (Engl Ed), 2018) [PMID:30545466]
- Introducción. Darunavir, cobicistat, emtricitabina y tenofovir alafenamida coformulados en el tratamiento de la infección por el VIH. (Enferm Infecc Microbiol Clin (Engl Ed), 2018) [PMID:30545465]
_Worker-drafted node — pending editorial review._
Connections
symtuza is a side effect of
Sources
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (2025) pubmed
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. (2018) pubmed
- Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D(2)EFT): an open-label, randomised, phase 3b/4 trial. (2024) pubmed
- Introducción. Darunavir, cobicistat, emtricitabina y tenofovir alafenamida coformulados en el tratamiento de la infección por el VIH. (2018) pubmed
- Symtuza(®) in clinical practice. (2018) pubmed
- Pharmacology of Symtuza(®) (DRV/c/FTC/TAF). (2018) pubmed
- Symtuza(®) (DRV/c/FTC/TAF) in the management of previously treated patients. (2018) pubmed
- Symtuza((®)) (DRV/c/FTC/TAF) in the management of treatment-naive HIV-patients. (2018) pubmed
- Tolerability of Current Antiretroviral Single-Tablet Regimens. (2018) pubmed
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa. (2025) pubmed